HER2 in-Situ hybridization positive breast cancers with HER2/CEP17 ratio ≥2.0 and average HER2 copy number <4.0 are frequently discordant with HER2 immunohistochemistry results: Implications for potential modification of testing algorithm

被引：0
|
作者：
Livasy, Chad
Johnson, Nicole
Domfeh, Akosua
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Levine Canc Inst, Charlotte, NC USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-20-08
引用
收藏
页数：1
相关论文
共 50 条
  • [1] HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average &lt;4.0 HER2 and &lt;2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy
    Livasy, Chad A.
    Limentani, Kimberly
    Calhoun, Benjamin C.
    Limentani, Steven
    CANCER RESEARCH, 2015, 75
  • [2] Breast Cancer With a HER2 IHC2+and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number &lt;4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
    Liu, Yuanyuan
    Wu, Shafei
    Shi, Xiaohua
    Mao, Feng
    Zeng, Xuan
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [3] Incidence and Significance of Fluorescent In Situ Hybridization (FISH) HER2 Gene Amplification by HER2 Gene Copy Number of ≥6.0 with Her2/CEP17 Ratio of &lt;2.0 in Breast Cancer
    Apple, Sophia
    MODERN PATHOLOGY, 2017, 30 : 29A - 30A
  • [4] Incidence and Significance of Fluorescent In Situ Hybridization (FISH) HER2 Gene Amplification by HER2 Gene Copy Number of ≥ 6.0 with Her2/CEP17 Ratio of &lt;2.0 in Breast Cancer
    Apple, Sophia
    LABORATORY INVESTIGATION, 2017, 97 : 29A - 30A
  • [5] A clinicopathological study and survival analysis of 99 breast cancers with HER2/CEP17 ratio ≥ 2.0 and an average HER2 copy number < 4.0 per cell in China
    Shuling Zhou
    Hong Lv
    Anqi Li
    Ming Li
    Siyuan Zhong
    Hongfen Lu
    Xiaoyan Zhou
    Qianming Bai
    Wentao Yang
    BMC Cancer, 23
  • [6] HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number &lt;4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Roma, Andres
    Dell'Aquila, Marie
    Hasteh, Farnaz
    Fadare, Oluwole
    MODERN PATHOLOGY, 2018, 31 : 117 - 117
  • [7] HER2/neu-Amplified Breast Cancers with HER2/CEP17 ratio ≥ 2.0 but with an Average HER2 Copy Number &lt;4.0 Signals/Cell: An Assessment of Frequency, Immunohistochemical Correlation, and Clinicopathologic Features
    Zare, Somaye
    Lin, Leo
    Alghamdi, Abrar G.
    Roma, Andres
    Dell'Aquila, Marie
    Hasteh, Farnaz
    Fadare, Oluwole
    LABORATORY INVESTIGATION, 2018, 98 : 117 - 117
  • [8] Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio &lt;2.0 and Average HER2 Copy Number ≥4.0 and &lt;6.0
    Hoda, Raza S.
    Brogi, Edi
    Xu, Jin
    Ventura, Katia
    Ross, Dara S.
    Dang, Chau
    Robson, Mark
    Norton, Larry
    Morrow, Monica
    Wen, Hannah Y.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2020, 144 (05) : 597 - 601
  • [9] A clinicopathological study of 30 breast cancer cases with a HER2/CEP17 ratio of ≥2.0 but an average HER2 copy number of <4.0 signals per cell
    Wang, Xiaoling
    Teng, Xiaodong
    Ding, Wei
    Sun, Ke
    Wang, Bo
    MODERN PATHOLOGY, 2020, 33 (08) : 1557 - 1562
  • [10] Utility of HER2 Immunohistochemistry in Clarifying HER2 Status in Breast Cancer with HER2:CEP17 Ratio &lt;2 and Average &gt;/=4.0 and &lt;6.0 HER2 Signals per Tumor Cell by Fluorescence in-situ Hybridization (Focused Update Group 4)
    Muller, Kristen
    Marotti, Jonathan
    Tafe, Laura
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 223 - 223
12345